Nonselective Beta-Adrenergic Antagonists

Beta-adrenergic blocking agents block pulmonary effects of albuterol and may produce severe bronchospasm in asthmatic patients.

Bisoprolol fumarate should not be combined with other beta-blocking agents.

Should not be combined with other beta-blocking agents due to additive effects.

Labetalol antagonizes the bronchodilatory effect of beta-receptor agonist drugs and is contraindicated in patients with bronchial asthma.

May block bronchodilatory effects and produce severe bronchospasm in asthmatic patients. Patients with asthma should not normally be treated with beta-blockers.

May block bronchodilatory effects and produce severe bronchospasm. Patients with asthma should not normally be treated with beta-blockers.

Block pulmonary effect of terbutaline and may produce severe bronchospasm in asthmatic patients. Should not normally be used in asthma patients.

Beta-blockers may inhibit therapeutic effects of formoterol and produce severe bronchospasm in COPD patients. Use with caution and only when medically necessary.

Beta-blockers block the pulmonary effect of albuterol and may produce severe bronchospasm in asthmatic patients. Patients with asthma should not normally be treated with beta-blockers.

May decrease effectiveness of albuterol and produce severe bronchospasm in asthma patients. Use cardioselective beta-blockers with caution when necessary.

Negative chronotrope. Potentiates electrophysiologic and hemodynamic effects resulting in bradycardia, sinus arrest, and AV block.

May decrease effectiveness and block bronchodilatory effects of arformoterol. Use with caution and only when medically necessary.

May produce severe, prolonged hypertension when combined with local anesthetic solutions containing epinephrine.

May produce severe, prolonged hypertension when local anesthetic solutions containing epinephrine are administered to patients receiving these agents.

May cause severe hypertension and bradycardia. Concurrent use should generally be avoided.

Concomitant use may potentiate systemic beta-blockade with additive effects on both systemic and intraocular pressure.

May block bronchodilatory effects of formoterol and produce severe bronchospasm in asthma patients. Use with extreme caution; avoid in asthma.

May cause severe hypertension and bradycardia. Concurrent use should generally be avoided.

May cause severe hypertension and bradycardia. Concurrent use should generally be avoided; if necessary, careful monitoring of blood pressure and heart rate is essential.

Beta-blockers may exacerbate the hypertensive response seen with clonidine withdrawal. Additive effects such as bradycardia and AV block may occur.

Potentiate bradycardia and risk of AV block. Caution is warranted.

Beta-blockers cause bradycardia and should be avoided with crizotinib, which can also cause bradycardia.

Patients receiving beta blockers may not be responsive to beta adrenergic drugs used to treat anaphylaxis. Temporary postponement of treatment on skin testing day may be considered.

Administration with Bupivacaine Hydrochloride and Epinephrine may cause severe hypertension and bradycardia. Concurrent use should generally be avoided.

Additive effects in prolonging AV conduction; concomitant use usually well tolerated but may cause problems in patients with left ventricular dysfunction or cardiac conduction abnormalities.

Concurrent use may increase risk for hypotension, bradycardia, and heart failure due to impaired cardiac contractility and conduction.

Potential additive effects of beta-blockade both systemically and on intraocular pressure. Concomitant use of two topical beta-adrenergic blocking agents is not recommended.

Oral beta-blockers with dorzolamide/timolol may produce additive systemic beta-blockade effects. Concomitant topical beta-blockers not recommended.

Limited experience; concomitant use during fingolimod initiation may cause severe bradycardia or heart block due to additive heart rate reduction.

Drugs that slow heart rate. Concomitant use during fingolimod initiation may cause severe bradycardia or heart block. Consider switching to alternative drugs.

Risk of severe bradycardia or heart block with concomitant use during TASCENSO ODT initiation. Limited experience in concurrent therapy.

May block bronchodilatory effects of vilanterol and produce severe bronchospasm in patients with COPD or asthma.

May block bronchodilatory effects of vilanterol and produce severe bronchospasm in COPD or asthma patients. Use with caution; cardioselective agents may be considered.

May block bronchodilatory effects of salmeterol and produce severe bronchospasm.

May inhibit therapeutic effects of formoterol and cause severe bronchospasm in COPD patients. Use only when medically necessary and with caution.

May block bronchodilatory effects of formoterol and produce severe bronchospasm. Use with caution; avoid in asthma patients.

Beta-adrenergic blocking agents may potentiate the hypoglycemic action of glyburide. Close observation for hypoglycemia required.

Beta-blockers lower the threshold for contrast reactions, increase severity of reactions, and reduce responsiveness to epinephrine treatment. Use caution when administering iodixanol to patients taking beta-blockers.

Increased risk of adverse cardiovascular effects with concomitant sympathomimetic agents. Avoid coadministration.

Concomitant use may exaggerate cardiovascular effects of isoflurane, including hypotension and negative inotropic effects.

May cause severe hypertension and bradycardia. Concurrent use should generally be avoided.

May block bronchodilatory effects and produce severe bronchospasm in asthmatic patients. Patients with asthma should not normally be treated with beta-blockers.

May block bronchodilatory effects of levalbuterol and produce severe bronchospasm. Patients with asthma should not normally be treated with beta-blockers.

Administration of lidocaine solutions containing epinephrine may cause severe hypertension and bradycardia. Concurrent use should generally be avoided.

May cause severe hypertension and bradycardia with possible heart block. Concurrent use should generally be avoided.

Administration with Bupivacaine Hydrochloride and Epinephrine may cause severe hypertension and bradycardia. Concurrent use should generally be avoided.

May impair reversal of methacholine chloride-caused bronchoconstriction.

Administration of Bupivacaine Hydrochloride and Epinephrine in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. Concurrent use should generally be avoided.

May decrease effectiveness of formoterol and produce severe bronchospasm. Use with caution only when medically necessary.

Concomitant use can potentiate electrophysiologic and hemodynamic effects, resulting in bradycardia, sinus arrest, and AV block.

Combination may increase likelihood of congestive heart failure, severe hypotension, or exacerbation of angina, though usually well tolerated.

Beta-blockers blunt reflex tachycardia but not hypotensive effects of nitroglycerin, potentially causing additional hypotension in angina patients.

May decrease effectiveness of olodaterol and produce severe bronchospasm in COPD patients. Use only when medically necessary with caution; cardioselective agents preferred.

Probenecid elevates plasma concentrations of beta-lactams, increasing incidence of adverse reactions including psychic disturbances.

Probenecid elevates plasma concentrations of beta-lactams, increasing incidence of adverse reactions including psychic disturbances.

Block bronchodilatory effects of salmeterol and may produce severe bronchospasm in asthma or COPD patients.

Beta-blockers may decrease effectiveness of olodaterol and produce severe bronchospasm in COPD patients. Use with caution and only when medically necessary.

May block bronchodilatory effects of vilanterol and produce severe bronchospasm in COPD patients. Avoid use; if necessary, use cardioselective beta-blockers with caution.

Serious adverse effects reported in rare instances with intravenous beta-blockers and intravenous verapamil, especially in severe cardiomyopathy, heart failure, or recent MI. May result in exaggerated hypotensive response.

Given with adenosine without apparent adverse interactions, but adenosine should be used with caution due to potential additive depressant effects on SA and AV nodes.

Caution advised due to potential additive hypotensive and pulse-reducing effects.

Aspirin may diminish the hypotensive effects of beta blockers through inhibition of renal prostaglandins.

Aspirin may diminish the hypotensive effects of beta blockers due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt/fluid retention.

Hypotensive effects of beta blockers may be diminished by aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt/fluid retention.

Potential additive effect on intraocular pressure or known systemic effects of beta blockade when beta-adrenergic blocking agent is given orally with Betaxolol Hydrochloride Ophthalmic Solution.

Alpha-2 agonists may reduce blood pressure; caution advised when using beta-blockers concurrently.

Alpha-2 agonists may reduce blood pressure; caution advised when used with beta-blockers due to potential additive hypotensive effects.

Additive effects on systemic beta-blockade when used orally with carteolol hydrochloride ophthalmic solution. Close observation recommended.

Concomitant use may diminish the antihypertensive effect. Monitor blood pressure.

Cevimeline should be administered with caution due to the possibility of conduction disturbances when used concurrently with beta adrenergic antagonists.

Monitor heart rate in patients receiving clonidine concomitantly with beta-blockers due to effects on sinus node function or AV nodal conduction.

Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given dasiglucagon.

Pseudoephedrine may reduce the antihypertensive effects of beta-adrenergic blocking agents. Exercise caution when used concomitantly.

Concomitant use requires adequate hydration and renal function assessment at beginning of treatment.

NSAIDs may diminish the antihypertensive effect of beta-blockers including propranolol.

May diminish antihypertensive effect. Monitor blood pressure.

When administered concomitantly, patients should be adequately hydrated and renal function assessed at baseline.

Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect. Monitor blood pressure.

Concomitant use may diminish the antihypertensive effect of beta-blockers.

NSAIDs may diminish the antihypertensive effect of beta-blockers including propranolol.

Although may be useful in combination with digoxin, additive effects on AV node conduction can result in advanced or complete heart block.

May provoke excessive bradycardia. Initiate with low dose and increase after ECG verification of tolerability.

May potentiate hypoglycemic action of glyburide; patient should be closely observed for hypoglycemia.

May lead to either potentiation or weakening of glimepiride's glucose-lowering effect. May also reduce signs of hypoglycemia.

Beta blockers may potentiate hypoglycemic action of glipizide. Patient should be observed closely for hypoglycemia when initiated or withdrawn.

Beta blockers may potentiate the hypoglycemic action of glipizide. Patient should be observed closely for hypoglycemia.

Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given glucagon. The increase may require therapy in patients with coronary artery disease.

Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given glucagon. The increase may require therapy in patients with coronary artery disease.

May potentiate hypoglycemic action of glyburide; monitor for hypoglycemia.

Use with caution and only when medically necessary. May antagonize effects of formoterol.

NSAIDs may diminish antihypertensive effect; monitor blood pressure during concomitant use.

May increase or decrease blood glucose lowering effect and may blunt signs/symptoms of hypoglycemia. Increased glucose monitoring may be required.

May increase or decrease blood glucose lowering effect and blunt signs/symptoms of hypoglycemia. Increased glucose monitoring required.

May increase or decrease blood glucose lowering effect and blunt hypoglycemia signs/symptoms. Dosage adjustment and increased glucose monitoring may be required.

May increase or decrease blood glucose-lowering effect and may blunt signs/symptoms of hypoglycemia; dosage adjustment and increased glucose monitoring required.

May increase or decrease blood glucose lowering effect and may blunt signs/symptoms of hypoglycemia. Dosage adjustment and increased glucose monitoring required.

May increase or decrease blood glucose lowering effect and blunt signs/symptoms of hypoglycemia. Dosage adjustment and increased glucose monitoring required.

May increase or decrease blood glucose lowering effect and may blunt signs/symptoms of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

May increase or decrease blood glucose lowering effect and blunt signs/symptoms of hypoglycemia. Dose adjustment and increased glucose monitoring required.

May increase or decrease blood glucose lowering effect and may blunt hypoglycemia signs/symptoms. Dosage adjustment and increased glucose monitoring required.

May increase or decrease blood glucose lowering effect and may blunt signs/symptoms of hypoglycemia. Dose adjustment and increased glucose monitoring required.

May increase or decrease blood glucose effect and blunt signs/symptoms of hypoglycemia; increased glucose monitoring required.

May increase or decrease blood glucose lowering effect and may blunt signs and symptoms of hypoglycemia. Increased glucose monitoring required.

May increase or decrease blood glucose lowering effect and blunt signs/symptoms of hypoglycemia. Dose adjustment and increased glucose monitoring required.

Negative chronotropes that increase risk of bradycardia with ivabradine. Monitor heart rate.

Labetalol can blunt the bronchodilator effect of beta-agonists in patients with bronchospasm; higher than normal anti-asthmatic doses may be required.

Lacosamide should be used with caution with beta-blockers due to risk of AV block, bradycardia, or ventricular tachyarrhythmia. ECG monitoring recommended.

Use with caution due to risk of AV block, bradycardia, or ventricular tachyarrhythmia. ECG monitoring before initiation and after titration is recommended.

Lanreotide may have additive effects with bradycardia-inducing drugs, reducing heart rate; dosage adjustment may be necessary.

Concomitant use with meloxicam may diminish the antihypertensive effect of beta-blockers. Monitor blood pressure.

Meloxicam may diminish antihypertensive effect of beta-blockers. Monitor blood pressure.

Hyperthyroidism increases clearance of beta blockers with high extraction ratio. Dose reduction may be needed when patient becomes euthyroid with methimazole treatment.

Caution advised; concomitant use may enhance the vasoconstrictive action of methylergonovine.

Concomitant administration may enhance the vasoconstrictive action of ergot alkaloids; caution should be exercised.

NSAIDs may diminish the antihypertensive effect of beta-blockers.

NSAIDs may diminish the antihypertensive effect of beta-blockers.

May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.

Beta-receptor blockers have been frequently administered concomitantly with nicardipine hydrochloride. The combination is well tolerated.

May cause additional hypotensive effects when used with nitroglycerin. Beta-blockers blunt reflex tachycardia without preventing hypotensive effects.

Concomitant administration of beta-blockers may have an additive effect on reduction of heart rate associated with octreotide.

Aspirin may diminish hypotensive effects of beta blockers by inhibiting renal prostaglandins and reducing renal blood flow.

Alpha-adrenergic agonists may impact blood pressure; caution advised when used with beta-blockers.

Alpha-adrenergic agonists may impact blood pressure; caution advised when using beta-blockers concurrently.

Pilocarpine should be administered with caution due to possibility of conduction disturbances.

Pilocarpine should be administered with caution due to possibility of conduction disturbances.

Concomitant use may diminish the antihypertensive effect of these drugs.

Caution advised when initiating PONVORY in patients on beta-blockers; temporary interruption may be needed due to additive heart rate lowering.

May produce unfavorable interactions with potassium supplements, risk of hyperkalemia.

Hyperthyroidism increases clearance of beta blockers. A reduced dose may be needed when hyperthyroid patients become euthyroid with propylthiouracil treatment.

Caution when initiating siponimod in patients on beta-blockers; temporary interruption may be needed due to additive heart rate-lowering effects.

Beta blockers may cause additive bradycardic effect with thalidomide and should be used with caution.

Concomitant use may potentiate systemic beta-blockade with additive effects on heart rate and intraocular pressure.

Potential additive effects of beta-blockade, both systemic and on intraocular pressure. Concomitant use of two topical beta-adrenergic blocking agents is not recommended.

Concomitant use of two topical beta-adrenergic blocking agents is not recommended. Patients receiving oral beta-blockers with timolol should be observed for additive effects of beta-blockade.

Compounds that quench active oxygen species or scavenge radicals would be expected to decrease VISUDYNE activity.

Used concomitantly with enalapril maleate without evidence of clinically significant adverse interactions.

Enalapril has been used concomitantly without evidence of clinically significant adverse interactions.

Terazosin has been combined with several beta-adrenergic blockers in controlled trials with no unexpected interactions observed.